SDZNY vs. STVN: Which Stock Is the Better Value Option?

Zacks compares Sandoz Group AG (SDZNY) and Stevanato Group (STVN) and identifies SDZNY as the better value play: SDZNY holds a Zacks Rank #2 (Buy) versus STVN's #3 (Hold) and posts a forward P/E of 22.38, PEG of 1.20 and P/B of 3.63 (Value grade B) versus STVN's forward P/E 34.66, PEG 2.03 and P/B 3.7 (Value grade C). The analysis highlights SDZNY's improving earnings estimate revisions and relatively cheaper forward valuation metrics as the rationale for preferring SDZNY in the Medical‑Drugs sector.

Analysis

Market structure: SDZNY (Zacks #2, forward P/E 22.4, PEG 1.20) is the immediate beneficiary of positive estimate revisions and a Value grade B; investors rotate away from higher multiple STVN (forward P/E 34.7, PEG 2.03) which looks expensive vs growth expectations. Expect relative flows into large-cap, cash-generative drug suppliers and away from niche/high-PE names; pricing power shifts toward companies with visible EPS momentum and lower PEG spreads (>~1.5 premium looks punitive).

Risk assessment: Tail risks include regulatory price controls on generics or quality recalls (1–5% annual probability but >30% downside on material recalls), ADR/currency moves (CHF/EUR/USD swings ±5–8% can move returns), and a surprise downgrade to SDZNY estimates. Near-term (days–weeks) volatility will track earnings/estimate windows; medium-term (3–9 months) depends on realized EPS beats; long-term (12+ months) depends on structural pricing in healthcare.

Trade implications: Primary trade is a long SDZNY / short STVN relative-value pair to capture P/E compression; target convergence of P/E spread from ~12 points to <5 within 3–9 months. Use option overlays: 3-month SDZNY call spreads (10% OTM) to lever without unlimited risk, and STVN 3-month put spreads to hedge downside; size initial exposure to 2–4% portfolio risk with 12–15% stop-loss thresholds.

Contrarian angles: Consensus underweights the probability that SDZNY’s estimate upgrades continue — if EPS revisions remain positive, re-rating to P/E 16–18 is realistic and would imply 25–40% upside. Conversely, shorting STVN risks a squeeze from beat-driven re-ratings or M&A; cap exposure accordingly and watch next 60 days of guidance and volume-driven option skew for signs of crowding.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in SDZNY immediately; add up to a total 4% on a pullback of 8–12%. Target a 20–35% upside over 6–12 months (re-rate to P/E 16–18) and set a hard stop at -15%.
• Implement a dollar-neutral pair trade: long SDZNY (3% notional) and short STVN (3% notional) for 3–9 months to capture expected P/E convergence (current spread ~12 points -> target <5). Cut the pair if spread widens >20% or after material company guidance changes.
• Use options to control risk: buy 3-month SDZNY call spreads (10% OTM buy / 20% OTM sell) sized to 0.5–1% portfolio risk; buy 3-month STVN put spreads (10–15% OTM) sized to 0.5% as hedge against surprise downside. Roll or exit after earnings or on implied vol rise >30%.
• Reduce 1–2% exposure to high-PE medical suppliers/packagers where STVN is a proxy; redeploy into SDZNY or other Zacks-ranked #1–2 healthcare names with Value grade A–B. Monitor estimate revisions and regulatory notices over the next 30–60 days as the primary catalyst triggers.